| pubmed-article:7689971 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C0060389 | lld:lifeskim |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C1704272 | lld:lifeskim |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C0042059 | lld:lifeskim |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:7689971 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:7689971 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7689971 | pubmed:dateCreated | 1993-10-7 | lld:pubmed |
| pubmed-article:7689971 | pubmed:abstractText | A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double-blind placebo-controlled study with finasteride (Proscar), a 5 alpha-reductase inhibitor, 5 mg or 10 mg/day, or an identical placebo for 3 months; subsequently, 20 patients received finasteride 5 mg/day in an open extension study. Ten of these patients have now completed 3 years of therapy and have been reevaluated with pressure/flow urodynamics. In finasteride-treated patients dihydrotestosterone (DHT) declined by over 60%, remaining unchanged with placebo. Symptom scores fell in both groups of patients, maximum flow rate values decreased on placebo but improved by a mean of 1.5 ml/s in the 10-mg group and 3.3 ml/s in the 5-mg group. After 1 year of therapy, the reduction in symptom score was well maintained and the flow rate had increased by a mean of 2.7 ml/s; the mean prostate volume was reduced by 14% and prostate-specific antigen (PSA) had declined by 28%. In the 10 patients treated for 3 years who consented to further urodynamic study, the maximum urinary flow rate had improved from a mean baseline value of 8.7 ml/s to a mean of 13.8 ml/s, while maximum subtracted voiding pressure had decreased from a mean baseline value of 72 cm H2O to an unobstructed mean value of 44 cm H2O. Side effects were minimal and reversible on stopping the medication.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7689971 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7689971 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689971 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7689971 | pubmed:issn | 0302-2838 | lld:pubmed |
| pubmed-article:7689971 | pubmed:author | pubmed-author:WebbJ AJA | lld:pubmed |
| pubmed-article:7689971 | pubmed:author | pubmed-author:ValeJJ | lld:pubmed |
| pubmed-article:7689971 | pubmed:author | pubmed-author:HolmesKK | lld:pubmed |
| pubmed-article:7689971 | pubmed:author | pubmed-author:BryanJJ | lld:pubmed |
| pubmed-article:7689971 | pubmed:author | pubmed-author:KirbyR SRS | lld:pubmed |
| pubmed-article:7689971 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7689971 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:7689971 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7689971 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7689971 | pubmed:pagination | 20-6 | lld:pubmed |
| pubmed-article:7689971 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:meshHeading | pubmed-meshheading:7689971-... | lld:pubmed |
| pubmed-article:7689971 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7689971 | pubmed:articleTitle | Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. | lld:pubmed |
| pubmed-article:7689971 | pubmed:affiliation | Department of Urology and Diagnostic Radiology, St. Bartholomew's Hospital, London, UK. | lld:pubmed |
| pubmed-article:7689971 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7689971 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7689971 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7689971 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7689971 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7689971 | lld:pubmed |
